GALECTIN-7 AS A BIOMARKER FOR DIAGNOSIS, PROGNOSIS AND MONITORING OF OVARIAN AND RECTAL CANCER

• US 20150330985A1
• Filed: 12/20/2012
• Published: 11/19/2015
• Est. Priority Date: 12/20/2012
• Status: Abandoned Application

• Current Assignee: Institut national de la recherche scientifique
• Original Assignee: Institut national de la recherche scientifique
• Inventors: St-Pierre, Yves
• Application Number:
  US14/654,195
• Publication Number:
  US 20150330985A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: G01N 2333/4703 Regulators; Modulating activity
• CPC Class Codes: G01N 33/57407 Specifically defined cancers
• CPC Class Codes: G01N 33/57419 of colon
• CPC Class Codes: G01N 33/57449 of ovaries
• CPC Class Codes: G16H 50/20 for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Methods, kits and systems for the diagnosis, prognosis and monitoring of ovarian cancer and rectal cancer are described. The methods, kits and systems are based on the detection of the lectin Galectin-7 in samples obtained from subjects.

Claims

1. A method for determining whether a subject has ovarian cancer or a predisposition to develop ovarian cancer, said method comprising:

(i) measuring the level of expression of Galectin-7 in an ovarian cell and/or tissue sample from said subject;

(ii) comparing said level of expression to a control level; and

(iii) determining whether said subject has ovarian cancer or a predisposition to develop ovarian cancer based on said comparison.

2. The method of claim 1, wherein (a) said control level is a level measured in a non-cancerous ovarian cell and/or tissue sample, and (i) a higher level of expression in the ovarian cell and/or tissue sample from said subject is indicative that said subject has ovarian cancer or a predisposition to develop ovarian cancer;

or (ii) a similar or lower level of expression in the ovarian cell and/or tissue sample from said subject is indicative that said subject does not have ovarian cancer or a predisposition to develop ovarian cancer;

or (b) said control level is a level measured in a cancerous ovarian cell and/or tissue sample, and (i) a similar or higher level of expression in the ovarian cell and/or tissue sample from said subject is indicative that said subject has ovarian cancer or a predisposition to develop ovarian cancer;

or (ii) a lower level of expression in the ovarian cell and/or tissue sample from said subject is indicative that said subject does not have ovarian cancer or a predisposition to develop ovarian cancer.

4. The method of claim 1, wherein the level of expression of Galectin-7 is measured at the protein level.

6. The method of claim 4, wherein the level of expression of Galectin-7 is measured using an antibody.

7. The method of claim 4, wherein the level of expression of Galectin-7 is measured by immunohistochemistry.

8. The method of claim 1, wherein said ovarian cell and/or tissue sample is a biopsy sample.

9. The method of claim 1, wherein said ovarian cancer is a mucinous carcinoma, a transitional cell carcinoma or an adenocarcinoma.

10. The method of claim 9, wherein said adenocarcinoma is endometrioid adenocarcinoma.

3. (canceled)

5. (canceled)

11. A method for determining whether a subject has rectal cancer or a predisposition to develop rectal cancer, said method comprising:

(iv) measuring the level of expression of Galectin-7 in a rectal cell and/or tissue sample from said subject;

(v) comparing said level of expression to a control level; and

(vi) determining whether said subject has rectal cancer or a predisposition to develop rectal cancer based on said comparison.

12. The method of claim 11, wherein (a) said control level is a level measured in a non-cancerous rectal cell and/or tissue sample, and (i) a higher level of expression in the rectal cell and/or tissue sample from said subject is indicative that said subject has rectal cancer or a predisposition to develop rectal cancer;

or (ii) a similar or lower level of expression in the rectal cell and/or tissue sample from said subject is indicative that said subject does not have rectal cancer or a predisposition to develop rectal cancer;

or (b) said control level is a level measured in a cancerous rectal cell and/or tissue sample, and (i) a similar or higher level of expression in the rectal cell and/or tissue sample from said subject is indicative that said subject has rectal cancer or a predisposition to develop rectal cancer;

or (ii) a lower level of expression in the rectal cell and/or tissue sample from said subject is indicative that said subject does not have rectal cancer or a predisposition to develop rectal cancer.

14. The method of claim 11, wherein the level of expression of Galectin-7 is measured at the protein level.

16. The method of claim 14, wherein the level of expression of Galectin-7 is measured using an antibody.

17. The method of claim 14, wherein the level of expression of Galectin-7 is measured by immunohistochemistry.

18. The method of claim 11, wherein said rectal cell and/or tissue sample is a biopsy sample.

13. (canceled)

15. (canceled)

19. A method for monitoring the progression of ovarian or rectal cancer in a subject, the method comprising:

(i) measuring the level of expression of Galectin-7 in a first ovarian or rectal cell and/or tissue sample from said subject at a first time point;

(ii) measuring the level of expression of Galectin-7 in a second ovarian or rectal cell and/or tissue sample from said subject at a later time point;

(iii) wherein (a) a level of expression of Galectin-7 that is higher in said second sample relative to said first sample is indicative that said ovarian or rectal cancer has progressed;

(b) a level of expression of Galectin-7 that is lower in said second sample relative to said first sample is indicative that said ovarian or rectal cancer has regressed;

or (c) a level of expression of Galectin-7 that is similar in said second sample relative to said first sample is indicative that said ovarian or rectal cancer is stable.

20. The method of claim 19, wherein the level of expression of Galectin-7 is measured at the protein level.

22. The method of claim 20, wherein the level of expression of Galectin-7 is measured using an antibody.

23. The method of claim 20, wherein the level of expression of Galectin-7 is measured by immunohistochemistry.

21. (canceled)

24-30. -30. (canceled)

31. An ovarian or rectal cancer diagnostic system comprising (i) an ovarian or rectal cell and/or tissue sample;

(ii) a Galectin-7 binding reagent; and

(iii) a device for detecting the presence and/or amount of Galectin-7/Galectin-7 binding reagent complexes.

32. (canceled)

33. A computer-readable medium comprising code for controlling one or more processors to classify whether an ovarian or rectal cell and/or tissue sample from an subject is associated with ovarian or rectal cancer, said code comprising:

instructions to apply a statistical process to a data set comprising a Galectin-7 profile to produce a statistically derived decision classifying said sample as an ovarian or rectal cancer sample or non-ovarian or rectal cancer sample based upon said Galectin-7 profile, wherein said Galectin-7 profile indicates the level of Galectin-7 in said ovarian or rectal cell and/or tissue sample.

34-37. -37. (canceled)